Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Barinthus Biotherapeutics (BRNS) Invested Capital (2020 - 2025)

Barinthus Biotherapeutics (BRNS) has disclosed Invested Capital for 6 consecutive years, with $84.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Invested Capital fell 46.97% year-over-year to $84.6 million, compared with a TTM value of $84.6 million through Sep 2025, down 46.97%, and an annual FY2024 reading of $130.0 million, down 30.46% over the prior year.
  • Invested Capital was $84.6 million for Q3 2025 at Barinthus Biotherapeutics, down from $102.5 million in the prior quarter.
  • Across five years, Invested Capital topped out at $254.8 million in Q2 2022 and bottomed at -$52.8 million in Q1 2021.
  • Average Invested Capital over 5 years is $181.2 million, with a median of $195.6 million recorded in 2023.
  • Peak annual rise in Invested Capital hit 954.6% in 2021, while the deepest fall reached 104.32% in 2021.
  • Year by year, Invested Capital stood at $252.7 million in 2021, then dropped by 3.77% to $243.2 million in 2022, then dropped by 23.11% to $187.0 million in 2023, then plummeted by 30.46% to $130.0 million in 2024, then crashed by 34.97% to $84.6 million in 2025.
  • Business Quant data shows Invested Capital for BRNS at $84.6 million in Q3 2025, $102.5 million in Q2 2025, and $115.6 million in Q1 2025.